What Recurrent Pregnancy Loss Means

Recurrent pregnancy loss is a distinct diagnosis, not simply bad luck repeated. ASRM defines it as the spontaneous loss of two or more pregnancies, excluding confirmed molar and ectopic pregnancies. A pregnancy confirmed by a urine or blood hCG test counts; ultrasound or tissue confirmation is not required, and biochemical losses are included. Losses before 22 weeks fall within this definition, and they do not have to be consecutive. In my practice I start by making sure we are describing the same thing, because the word “miscarriage” is used loosely and the evaluation depends on an accurate history.

The goal of an evaluation is not to assign blame. It is to look for a cause that can be treated or managed, and to give you a realistic sense of what lies ahead. Roughly half of couples receive a putatively identified diagnosis. The other half are told their losses are unexplained — difficult to hear, but not the same as having no chance. Expectant management alone is followed by a successful next pregnancy for a majority of patients. I will return to one point throughout: the numbers I quote describe groups of patients, not a forecast for you as an individual.

How Common Is It

Miscarriage is common. Clinically recognized pregnancy loss occurs in roughly 15 to 25 percent of pregnancies, and most sporadic losses before 10 weeks result from random chromosome errors. Only a small share of couples go on to have repeated losses: fewer than five percent of women experience two consecutive miscarriages, and about one percent experience three or more. About 50 to 60 percent of first-trimester miscarriages are due to embryonic aneuploidy — an incorrect number of chromosomes — and this becomes more frequent with maternal age.

Those are population figures. They help a clinician frame a conversation; they cannot tell you why your losses happened or whether your next pregnancy will succeed. Patients often arrive having read a percentage online and understandably want it applied to themselves. I would resist that. Your age, the number and timing of losses, any chromosome testing, and your overall health all shift the picture in ways a single statistic cannot capture. Our guide to age and fertility explains why maternal age influences chromosome error rates.

The Main Causes

When a cause is identified, it usually falls into one of several groups. Chromosomal factors include a balanced translocation carried by one parent, found in roughly two to five percent of couples with recurrent loss. Anatomic factors involve the shape of the uterus, fibroids, polyps, scar tissue, or an incompetent cervix; congenital uterine anomalies appear in about 13 percent of women with recurrent loss compared with roughly five to six percent of the general population. Antiphospholipid syndrome is an immune-related clotting disorder that can be treated. Hormonal and metabolic conditions — uncontrolled thyroid disease or diabetes, for example — can contribute. Lifestyle exposures and, in some cases, sperm factors play a role. In a substantial fraction of couples, no single cause is found even after a careful workup.

It helps to separate one sporadic chromosome error from a recurring pattern. A single early loss with an abnormal chromosome count is usually a random event and does not, on its own, predict another. Recurrent loss is evaluated differently precisely because the odds of a repeated, explainable cause are higher.

Chromosome Testing of the Miscarriage

ASRM now recommends offering chromosome analysis of miscarriage tissue to all patients having their second miscarriage or with a history of recurrent loss, using array-based technology. There are three practical reasons. First, it often provides an explanation — about half of first-trimester losses show aneuploidy, rising to roughly 75 percent of tested losses in women over 40. Second, finding a sporadic aneuploidy can spare a couple a costly and inconclusive workup. Third, and importantly, many patients tell us that an answer reduces feelings of guilt and self-blame.

The result also guides the next step. If the miscarriage tissue shows an abnormal chromosome count, the evaluation may reasonably stop there, since that pattern is usually sporadic rather than inherited. If it shows a normal (euploid) chromosome count, we look harder for a uterine, hormonal, immune, or paternal explanation. This is where genetic testing in IVF becomes relevant to the conversation, although testing an embryo is a different question from testing miscarriage tissue — a distinction I return to below.

Evaluating the Uterus, Hormones, and Metabolism

Imaging of the uterine cavity is recommended for all patients with recurrent loss. Depending on the situation this may be a hysterosalpingogram, a saline sonogram, or hysteroscopy, sometimes with three-dimensional ultrasound. The purpose is to find structural problems — a septum, fibroids, polyps, adhesions, or a congenital anomaly — that might be correctable.

Blood work is targeted rather than blanket. Thyroid-stimulating hormone is checked, particularly with risk factors, symptoms, or a euploid loss. Hemoglobin A1c is checked when diabetes risk factors are present, such as obesity, age over 40, or PCOS. Prolactin is measured only when symptoms suggest it, such as irregular ovulation or nipple discharge. ASRM does not recommend routine ovarian reserve testing in the recurrent loss workup, because the link is unclear and no treatment follows from the result; for background on what these tests measure, see AMH and ovarian reserve.

Antiphospholipid Syndrome and Immune Testing

Antiphospholipid syndrome deserves specific attention because it is a treatable cause. Testing looks for lupus anticoagulant, anticardiolipin IgG and IgM, and beta-2 glycoprotein I IgG and IgM antibodies, usually when the history fits — for example, three or more consecutive losses or a personal history of thrombosis. For patients with persistent, moderate-to-high antibody titers, treatment with prophylactic heparin plus low-dose aspirin is a recognized approach.

Beyond antiphospholipid syndrome, the immune testing marketed for recurrent loss is not supported. ASRM does not recommend inherited thrombophilia panels, testing for thyroid antibodies outside of antiphospholipid syndrome, natural killer cell testing, endometrial receptivity testing, or microbiome testing, and it does not recommend routine immune testing and treatment. This is one of the clearest gaps between what is sometimes offered directly to patients and what professional guidelines endorse. If a clinic proposes a broad immune panel, ask which result would change the plan and what evidence supports the treatment that follows.

Treatments the Evidence Does Not Support

This section may be the most useful one in the guide. For unexplained recurrent loss, studies have not shown benefit from low-dose aspirin, enoxaparin, glucocorticoids, heparin, endometrial scratching, granulocyte colony-stimulating factor, intralipid therapy, routine vaginal progesterone, intravenous immunoglobulin, or lymphocyte immunization. ASRM expressly advises against routine use of these treatments, and against anticoagulants for hereditary thrombophilia or unexplained loss, on the basis of high-quality evidence showing no improvement in live birth or miscarriage rates.

Why does this matter? An intervention that sounds reasonable can still carry cost, side effects, and the heavier harm of raising hopes evidence cannot justify. Shared decision-making means being told when a treatment is unproven, not only when it is available. Our fertility FAQs cover other claims patients encounter and help you sort advice from evidence.

Where IVF and Genetic Testing Fit

IVF is not automatically the answer to recurrent loss. Expectant management — trying again with early monitoring and no specific intervention — is followed by a successful pregnancy in roughly 50 to 80 percent of patients with unexplained recurrent loss, depending on age and parity. That is a population figure and should be read as reassurance about the group, not a guarantee for you.

There are situations where treatment changes the odds. When one partner carries a balanced translocation, options include IVF with preimplantation genetic testing for structural rearrangements, or the use of donor gametes; genetic counseling is an essential part of that decision. The role of PGT-A in recurrent loss is more limited than many patients expect. ASRM’s 2026 committee opinion concludes that PGT-A has not been shown to significantly reduce miscarriage or improve live births compared with expectant management in this setting. In women over 40 with a proven aneuploid miscarriage, discussing PGT-A is reasonable, but patients should be told that it has not been shown to shorten the time to a successful pregnancy or raise the live birth rate. Our detailed guide to PGT in IVF explains the technology and its limits; IUI versus IVF explains where these treatments sit in the broader pathway.

Lifestyle, Age, and Male Factors

Some practical steps are worth taking regardless of the cause. Smoking cessation is strongly recommended, and exposures such as alcohol and high caffeine intake are best reduced before conception; maintaining a healthy weight is also sensible. These are population-level risk reductions, not a claim that lifestyle changes alone will prevent another loss — and they should never be used to imply that a patient caused a miscarriage.

Maternal age is one of the strongest influences on chromosome errors in early pregnancy, and our guide to age and fertility covers that in detail. Paternal factors are sometimes overlooked: ASRM lists sperm DNA fragmentation testing among the tests to consider in recurrent unexplained miscarriage or when infertility coexists. When that is relevant, evaluation of the male partner belongs in the same conversation; male infertility and semen analysis explains what is usually assessed.

Questions Patients Ask Most

How many losses before I should be evaluated?

ASRM defines recurrent pregnancy loss as two or more spontaneous losses, and an evaluation may begin after two. Biochemical losses confirmed by hCG count. Some clinicians start sooner when the history or other findings warrant it, so a consultation is the right place to decide.

Does an early ultrasound or home test change the definition?

No. A pregnancy confirmed by urine or blood hCG is sufficient. Ultrasound or tissue confirmation is not required, and biochemical losses are included because they appear to carry a similar recurrence risk.

Will I ever carry a pregnancy to term?

Most patients can. With no specific intervention, roughly 50 to 80 percent of those with unexplained recurrent loss go on to a successful pregnancy. That range describes groups of patients; your own outlook depends on age, the cause if one is found, and your general health.

Should I ask for PGT?

Not routinely. In recurrent loss, PGT-A has not been shown to reduce miscarriage or improve live birth rates compared with expectant management. It may be worth discussing in women over 40 with a proven aneuploid loss, and it has a clearer role when a parent carries a structural chromosome rearrangement.

Are immune or blood-thinning treatments worth trying?

For unexplained recurrent loss, high-quality evidence shows no benefit from empiric aspirin, heparin, IVIG, intralipids, or similar protocols. Treatment is appropriate when a specific diagnosis such as antiphospholipid syndrome is confirmed — not as a general precaution.

Key Takeaways

  • ASRM defines recurrent pregnancy loss as two or more spontaneous losses, including biochemical losses, before 22 weeks; losses need not be consecutive.
  • About half of couples get a defined diagnosis; in the rest, the losses remain unexplained.
  • Embryonic aneuploidy causes roughly 50 to 60 percent of first-trimester miscarriages and becomes more common with maternal age.
  • Chromosome analysis of miscarriage tissue is recommended from the second loss and can guide whether further testing is needed.
  • Uterine cavity evaluation is recommended for all patients; thyroid and diabetes testing is targeted rather than routine.
  • Antiphospholipid syndrome is treatable, but broad immune, thrombophilia, and microbiome testing are not recommended.
  • For unexplained loss, common empiric treatments — aspirin, heparin, IVIG, intralipids, endometrial scratching — have not been shown to improve live birth rates.
  • With no specific intervention, roughly 50 to 80 percent of patients with unexplained recurrent loss have a successful next pregnancy; that is a population figure, not a personal prediction.

Taking the Next Step

A good first appointment should review the exact history of each loss, discuss whether chromosome testing of tissue is available, and explain which evaluations are recommended and which are not. If you are learning the terminology, our fertility FAQs are a useful start; if a structural chromosome issue or IVF is on the table, read genetic testing in IVF alongside IUI versus IVF. Ask us which tests would change your plan — a clear answer is the mark of an evidence-based workup.